Composition comprising a Survivin oligonucleotide and gemcitabine for the treatment of cancer

Details for Australian Patent Application No. 2005240020 (hide)

Owner Eli Lilly and Company

Inventors Patel, Bharvin Kumar

Agent Spruson & Ferguson

Pub. Number AU-B-2005240020

PCT Pub. Number WO2005/107771

Priority 60/564,540 22.04.04 US

Filing date 15 April 2005

Wipo publication date 17 November 2005

Acceptance publication date 10 February 2011

International Classifications

A61K 31/7068 (2006.01)

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/107771 Priority application(s): WO2005/107771

10 February 2011 Application Accepted

  Published as AU-B-2005240020

9 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005240022-Peripheral vascular occlusion devices

2005240012-Facet joint prosthesis measurement and implant tools